BRIACELL THERAP (BCTX) vs Celularity, Inc. (CELU)
BRIACELL THERAP and Celularity, Inc. are both Biotechnology companies. BRIACELL THERAP and Celularity, Inc. are of similar size ($38.2M and $37.2M). Celularity, Inc. has negative trailing earnings, so its P/E is not meaningful; BRIACELL THERAP trades at 1.9×. BRIACELL THERAP has the higher net margin (0.00% vs −345.8%) and the lower return on invested capital (−3,311.0% vs −1,070.9%). Across the 13 metrics below, Celularity, Inc. leads on 8 and BRIACELL THERAP on 5.
Valuation
Profitability
| Metric | BCTX | CELU | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 24.39% | 65.16% |
| Operating margin | 0.00% | (230.92%) | 0.00% |
| Net margin | 0.00% | (345.76%) | 0.00% |
| Free cash flow margin | 0.00% | (49.92%) | 0.00% |
| Return on equity | (173.55%) | 628.23% | (57.72%) |
| Return on assets | (139.20%) | (76.50%) | (49.22%) |
| Return on invested capital | (3,311.00%) | (1,070.92%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack